Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Overseas Pharmaceuticals Ltd. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, which means that each active case is being reviewed by a different individual. This distribution requires the company to manage two separate examiner relationships, as there is no overlap in the personnel currently reviewing these matters.
Despite the involvement of 2 distinct examiners, the portfolio's current activity is concentrated within 1 distinct art unit. This indicates that while the 2 pending office actions are being handled by different people, they are both being evaluated within the same technical department at the patent office. The busiest examiner, ISNOR, ALEXANDRA NICOLE, is responsible for 1 busiest examiner pending office action. Since the total number of pending office actions is 2 and there are 2 distinct examiners, each examiner is currently handling exactly 1 action. The concentration of 2 pending office actions in 1 distinct art unit provides a consistent technical environment for the company's prosecution, even as it navigates the styles of 2 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ISNOR, ALEXANDRA NICOLE | 1 | 28.6% | +23.7% |
| TRAN, SUSAN T | 1 | 62.8% | +35.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860709 | PROLONGED-RELEASE ORAL SOLID FORMULATION OF PIRFENIDONE | ISNOR, ALEXANDRA NICOLE | — |
| 18288382 | SLEEP-REGULATING TABLET ALLOWING RELEASE BY STAGES AND PREPARATION METHOD THEREOF | TRAN, SUSAN T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860709 | PROLONGED-RELEASE ORAL SOLID FORMULATION OF PIRFENIDONE | ISNOR, ALEXANDRA NICOLE | — |
| 18288382 | SLEEP-REGULATING TABLET ALLOWING RELEASE BY STAGES AND PREPARATION METHOD THEREOF | TRAN, SUSAN T | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18860709 | PROLONGED-RELEASE ORAL SOLID FORMULATION OF PIRFENIDONE | ISNOR, ALEXANDRA NICOLE | 1615 | §103§112 | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18288382 | SLEEP-REGULATING TABLET ALLOWING RELEASE BY STAGES AND PREPARATION METHOD THEREOF | TRAN, SUSAN T | 1615 | §102§103§112 | Non-Final OA | — | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial